Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

1.

miR-342 is associated with estrogen receptor-α expression and response to tamoxifen in breast cancer.

He YJ, Wu JZ, Ji MH, Ma T, Qiao EQ, Ma R, Tang JH.

Exp Ther Med. 2013 Mar;5(3):813-818. Epub 2013 Jan 22.

PMID:
23408138
[PubMed]
Free PMC Article
2.

Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer.

Yoshimoto N, Toyama T, Takahashi S, Sugiura H, Endo Y, Iwasa M, Fujii Y, Yamashita H.

Breast Cancer Res Treat. 2011 Nov;130(1):331-9. doi: 10.1007/s10549-011-1672-2. Epub 2011 Jul 14.

PMID:
21755340
[PubMed - indexed for MEDLINE]
3.

miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer.

Kondo N, Toyama T, Sugiura H, Fujii Y, Yamashita H.

Cancer Res. 2008 Jul 1;68(13):5004-8. doi: 10.1158/0008-5472.CAN-08-0180.

PMID:
18593897
[PubMed - indexed for MEDLINE]
Free Article
4.

MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer.

Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ.

J Biol Chem. 2008 Nov 7;283(45):31079-86. doi: 10.1074/jbc.M806041200. Epub 2008 Sep 12.

PMID:
18790736
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.

Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J, Perrot-Applanat M.

Cancer Res. 2002 Sep 1;62(17):4977-84.

PMID:
12208749
[PubMed - indexed for MEDLINE]
Free Article
6.

Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors.

Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME, Jones FE.

Carcinogenesis. 2010 Dec;31(12):2049-57. doi: 10.1093/carcin/bgq192. Epub 2010 Sep 27.

PMID:
20876285
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples.

Xiong J, Yu D, Wei N, Fu H, Cai T, Huang Y, Wu C, Zheng X, Du Q, Lin D, Liang Z.

FEBS J. 2010 Apr;277(7):1684-94. doi: 10.1111/j.1742-4658.2010.07594.x. Epub 2010 Feb 17.

PMID:
20180843
[PubMed - indexed for MEDLINE]
8.

Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.

Han Y, Yang L, Suarez-Saiz F, San-Marina S, Cui J, Minden MD.

Mol Cancer Res. 2008 Aug;6(8):1347-55. doi: 10.1158/1541-7786.MCR-07-2179.

PMID:
18708366
[PubMed - indexed for MEDLINE]
Free Article
9.

Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients.

Ijichi N, Shigekawa T, Ikeda K, Horie-Inoue K, Shimizu C, Saji S, Aogi K, Tsuda H, Osaki A, Saeki T, Inoue S.

Horm Cancer. 2012 Aug;3(4):147-59. doi: 10.1007/s12672-012-0111-0. Epub 2012 Apr 3.

PMID:
22476979
[PubMed - indexed for MEDLINE]
10.

Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy.

Bieche I, Parfait B, Le Doussal V, Olivi M, Rio MC, Lidereau R, Vidaud M.

Cancer Res. 2001 Feb 15;61(4):1652-8.

PMID:
11245479
[PubMed - indexed for MEDLINE]
Free Article
11.

MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer.

Cochrane DR, Cittelly DM, Howe EN, Spoelstra NS, McKinsey EL, LaPara K, Elias A, Yee D, Richer JK.

Horm Cancer. 2010 Dec;1(6):306-19. doi: 10.1007/s12672-010-0043-5.

PMID:
21761362
[PubMed - indexed for MEDLINE]
12.

Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.

Leary AF, Drury S, Detre S, Pancholi S, Lykkesfeldt AE, Martin LA, Dowsett M, Johnston SR.

Clin Cancer Res. 2010 Mar 1;16(5):1486-97. doi: 10.1158/1078-0432.CCR-09-1764. Epub 2010 Feb 23.

PMID:
20179226
[PubMed - indexed for MEDLINE]
Free Article
13.
14.

Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells.

Dardes RC, Schafer JM, Pearce ST, Osipo C, Chen B, Jordan VC.

Gynecol Oncol. 2002 Jun;85(3):498-506.

PMID:
12051881
[PubMed - indexed for MEDLINE]
15.

MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.

Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S, Majumder S.

J Biol Chem. 2008 Oct 31;283(44):29897-903. doi: 10.1074/jbc.M804612200. Epub 2008 Aug 15.

PMID:
18708351
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.

Girault I, Lerebours F, Amarir S, Tozlu S, Tubiana-Hulin M, Lidereau R, Bièche I.

Clin Cancer Res. 2003 Apr;9(4):1259-66.

PMID:
12684393
[PubMed - indexed for MEDLINE]
Free Article
17.

FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer.

Shigekawa T, Ijichi N, Ikeda K, Horie-Inoue K, Shimizu C, Saji S, Aogi K, Tsuda H, Osaki A, Saeki T, Inoue S.

Horm Cancer. 2011 Oct;2(5):286-97. doi: 10.1007/s12672-011-0082-6.

PMID:
21901488
[PubMed - indexed for MEDLINE]
18.

Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth.

Tolhurst RS, Thomas RS, Kyle FJ, Patel H, Periyasamy M, Photiou A, Thiruchelvam PT, Lai CF, Al-Sabbagh M, Fisher RA, Barry S, Crnogorac-Jurcevic T, Martin LA, Dowsett M, Charles Coombes R, Kamalati T, Ali S, Buluwela L.

Breast Cancer Res Treat. 2011 Jul;128(2):357-68. doi: 10.1007/s10549-010-1122-6. Epub 2010 Aug 22.

PMID:
20730598
[PubMed - indexed for MEDLINE]
19.
20.

Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.

Rydén L, Jirström K, Bendahl PO, Fernö M, Nordenskjöld B, Stål O, Thorstenson S, Jönsson PE, Landberg G.

J Clin Oncol. 2005 Jul 20;23(21):4695-704.

PMID:
16034044
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk